Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options

Our study represents the largest to date exploring the various manifestations of IMC, along with associated treatment approaches and outcomes. We found that its features overlap with those of different inflammatory colitides. Both infliximab and vedolizumab were equally effective in achieving symptom remission; however, infliximab was associated with a shorter time to response. As the number of patients affected by IMC continues to grow, larger-scale studies will be essential to validate and expand upon these findings.

Authors

Institutions

Publication Details

Journal
Journal of the National Comprehensive Cancer Network
Published
2025-09-01
DOI
https://doi.org/10.6004/jnccn.2025.7046
Citations
1
Primary Topic
Microscopic Colitis
Type
article
Field-Weighted Citation Impact
1.35
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options

Tanvi Gupta, Douglas Buckner Johnson, Hamza Adel Salim, Carolina Colli Cruz et al.
1 citations
Journal of the National Comprehensive Cancer Network
Microscopic Colitis
1.35
article

Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options

Tanvi Gupta, Douglas Buckner Johnson, Hamza Adel Salim, Carolina Colli Cruz, Anusha Shirwaikar Thomas, Kian Abdul-Baki, Kei Takigawa, Stéphane Champiat, Linfeng Lu, Karen Kim, Malek Shatila, Varun Vemulapalli, Andrew Sullivan, Ayesha Khan, Elliot Baerman, Cristina Natha, Yinghong Wang, Irene Lee, Raakhi Menon, Andres Caleb Urias Rivera, Krishnavathana Varatharajalu
article en
1 citations

Abstract

Our study represents the largest to date exploring the various manifestations of IMC, along with associated treatment approaches and outcomes. We found that its features overlap with those of different inflammatory colitides. Both infliximab and vedolizumab were equally effective in achieving symptom remission; however, infliximab was associated with a shorter time to response. As the number of patients affected by IMC continues to grow, larger-scale studies will be essential to validate and expand upon these findings.

Journal of the National Comprehensive Cancer NetworkVol. 23(9)
The University of Texas MD Anderson Cancer Center (US), Baylor College of Medicine (US), Vanderbilt University (US), Stanford Medicine (US), Memorial Hermann–Texas Medical Center (US), The University of Texas Health Science Center (US), The University of Texas Medical Branch at Galveston (US), The University of Texas Health Science Center at Houston (US)
Openalex Percentile: Top 16%
Microscopic Colitis
1.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.